Gilead Sciences, Inc. (GILD)
| Previous close | 67.29 |
| Open | 67.18 |
| Bid | 67.21 x 400 |
| Ask | 67.47 x 400 |
| Day's range | 66.97 - 67.34 |
| 52-week range | 64.33 - 87.87 |
| Volume | |
| Avg. volume | 6,903,904 |
| Market cap | 83.885B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 187.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.58%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
- Business Wire
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
- Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
